Alogliptin benzoate for management of type 2 diabetes

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well tolerated because of their low risk of hypoglycemia and other adverse events. Moreover, with their potential to improve beta cell function, a core defect of type 2 diabetes, DPP-4 inhibitors are becoming a major component of treatment of type 2 diabetes. Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. Once-daily administration of alogliptin as either monotherapy or combination therapy with other oral antidiabetic drugs or insulin has a potent glucose-lowering effect which is similar to that of other DPP-4 inhibitors, with a low risk of hypoglycemia and weight gain. The cardiovascular safety of this drug has been confirmed in a recent randomized controlled trial. This review summarizes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

Original languageEnglish
Pages (from-to)229-243
Number of pages15
JournalVascular Health and Risk Management
Volume11
DOIs
Publication statusPublished - 2015 Apr 10

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Benzoates
Type 2 Diabetes Mellitus
Incretins
Hypoglycemia
Hypoglycemic Agents
Insulin
Dipeptidyl Peptidase 4
Safety
Cardiovascular Agents
Glucose
Glucagon
Weight Gain
alogliptin
Randomized Controlled Trials
Enzymes

Keywords

  • Alogliptin
  • Dipeptidyl peptidase-4 inhibitor
  • Efficacy
  • Safety
  • Type 2 diabetes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

Alogliptin benzoate for management of type 2 diabetes. / Saisho, Yoshifumi.

In: Vascular Health and Risk Management, Vol. 11, 10.04.2015, p. 229-243.

Research output: Contribution to journalArticle

@article{a05169f215194ff08060943cb207584b,
title = "Alogliptin benzoate for management of type 2 diabetes",
abstract = "Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well tolerated because of their low risk of hypoglycemia and other adverse events. Moreover, with their potential to improve beta cell function, a core defect of type 2 diabetes, DPP-4 inhibitors are becoming a major component of treatment of type 2 diabetes. Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. Once-daily administration of alogliptin as either monotherapy or combination therapy with other oral antidiabetic drugs or insulin has a potent glucose-lowering effect which is similar to that of other DPP-4 inhibitors, with a low risk of hypoglycemia and weight gain. The cardiovascular safety of this drug has been confirmed in a recent randomized controlled trial. This review summarizes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.",
keywords = "Alogliptin, Dipeptidyl peptidase-4 inhibitor, Efficacy, Safety, Type 2 diabetes",
author = "Yoshifumi Saisho",
year = "2015",
month = "4",
day = "10",
doi = "10.2147/VHRM.S68564",
language = "English",
volume = "11",
pages = "229--243",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Alogliptin benzoate for management of type 2 diabetes

AU - Saisho, Yoshifumi

PY - 2015/4/10

Y1 - 2015/4/10

N2 - Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well tolerated because of their low risk of hypoglycemia and other adverse events. Moreover, with their potential to improve beta cell function, a core defect of type 2 diabetes, DPP-4 inhibitors are becoming a major component of treatment of type 2 diabetes. Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. Once-daily administration of alogliptin as either monotherapy or combination therapy with other oral antidiabetic drugs or insulin has a potent glucose-lowering effect which is similar to that of other DPP-4 inhibitors, with a low risk of hypoglycemia and weight gain. The cardiovascular safety of this drug has been confirmed in a recent randomized controlled trial. This review summarizes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

AB - Dipeptidyl peptidase-4 (DPP-4) inhibitors, a new class of oral hypoglycemic agents, augment glucose-dependent insulin secretion and suppress glucagon levels through enhancement of the action of endogenous incretin by inhibiting DPP-4, an incretin-degrading enzyme. DPP-4 inhibitors are generally well tolerated because of their low risk of hypoglycemia and other adverse events. Moreover, with their potential to improve beta cell function, a core defect of type 2 diabetes, DPP-4 inhibitors are becoming a major component of treatment of type 2 diabetes. Alogliptin benzoate is a newly developed, highly selective DPP-4 inhibitor which has been approved in many countries throughout the world. Once-daily administration of alogliptin as either monotherapy or combination therapy with other oral antidiabetic drugs or insulin has a potent glucose-lowering effect which is similar to that of other DPP-4 inhibitors, with a low risk of hypoglycemia and weight gain. The cardiovascular safety of this drug has been confirmed in a recent randomized controlled trial. This review summarizes the efficacy and safety of alogliptin, and discusses the role of DPP-4 inhibitors in the treatment of type 2 diabetes.

KW - Alogliptin

KW - Dipeptidyl peptidase-4 inhibitor

KW - Efficacy

KW - Safety

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84936770087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84936770087&partnerID=8YFLogxK

U2 - 10.2147/VHRM.S68564

DO - 10.2147/VHRM.S68564

M3 - Article

C2 - 25914541

AN - SCOPUS:84936770087

VL - 11

SP - 229

EP - 243

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

ER -